

1-1-2016

Effect of the IL-1 Receptor Antagonist Kineret® on Disease Phenotype in mdx Mice.

Margaret E. Benny Klimek

Arpana Sali

Children's National Medical Center, Washington, DC

Sree Rayavarapu

George Washington University

Jack Van der Meulen

Children's National Medical Center, Washington, DC

Kanneboyina Nagaraju

George Washington University

Follow this and additional works at: http://hsrc.himmelfarb.gwu.edu/smhs_intsysbio_facpubs



Part of the [Amino Acids, Peptides, and Proteins Commons](#), [Integrative Biology Commons](#), and the [Systems Biology Commons](#)

APA Citation

Klimek, M. E., Sali, A., Rayavarapu, S., Van der Meulen, J., & Nagaraju, K. (2016). Effect of the IL-1 Receptor Antagonist Kineret® on Disease Phenotype in mdx Mice. *PLoS One*, 11 (5). <http://dx.doi.org/10.1371/journal.pone.0155944>

This Journal Article is brought to you for free and open access by the Genomics and Precision Medicine at Health Sciences Research Commons. It has been accepted for inclusion in Genomics and Precision Medicine Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please contact hsrc@gwu.edu.

RESEARCH ARTICLE

Effect of the IL-1 Receptor Antagonist Kineret[®] on Disease Phenotype in *mdx* Mice

Margaret E. Benny Klimek¹, Arpana Sali¹, Sree Rayavarapu¹, Jack H. Van der Meulen¹, Kanneboyina Nagaraju^{1,2*}

1 Research Center for Genetic Medicine, Children's National Medical Center, Washington, District of Columbia, United States of America, **2** Department of Integrative Systems Biology, The George Washington University, Washington, District of Columbia, United States of America

* knagaraju@cnmcresearch.org



OPEN ACCESS

Citation: Benny Klimek ME, Sali A, Rayavarapu S, Van der Meulen JH, Nagaraju K (2016) Effect of the IL-1 Receptor Antagonist Kineret[®] on Disease Phenotype in *mdx* Mice. PLoS ONE 11(5): e0155944. doi:10.1371/journal.pone.0155944

Editor: Ashok Kumar, University of Louisville School of Medicine, UNITED STATES

Received: January 13, 2016

Accepted: May 7, 2016

Published: May 23, 2016

Copyright: © 2016 Benny Klimek et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper.

Funding: K.N. is supported by the National Institutes of Health (5U54HD053177, K26OD011171, P50AR060836-01), <http://www.nih.gov/>, the Muscular Dystrophy Association, <http://www.mda.org/>, the US Department of Defense (W81XWH-05-1-0616, W81XWH-11-1-0782, W81XWH-11-1-0330), <http://www.defense.gov/>, and NICHD (P50AR060836-01, National Center for Medical Rehabilitation Research), <https://www.nichd.nih.gov/Pages/index.aspx>. The funders had no role in study design, data collection

Abstract

Duchenne muscular dystrophy (DMD) is an X-linked muscle disease caused by mutations in the dystrophin gene. The pathology of DMD manifests in patients with progressive muscle weakness, loss of ambulation and ultimately death. One of the characteristics of DMD is muscle inflammation, and dystrophin-deficient skeletal muscles produce higher levels of the pro-inflammatory cytokine interleukin 1 β (IL-1 β) in response to toll like receptor (TLR) stimulation compared to controls; therefore, blocking the IL-1 β pathway could improve the disease phenotype in *mdx* mice, a mouse model of DMD. Kineret[®] or IL-1Ra is a recombinant IL-1 receptor antagonist approved by the FDA for treating rheumatoid arthritis. To determine the efficacy of IL-1Ra in a DMD model, we administered subcutaneous injections of saline control or IL-1Ra (25 mg/kg/day) to *mdx* mice daily for 45 days beginning at 5 weeks of age. Functional and histological parameters were measured at the conclusion of the study. IL-1Ra only partially inhibited this signaling pathway in this study; however, there were still interesting observations to be noted. For example, although not significantly changed, splenocytes from the IL-1Ra-treated group secreted less IL-1 β after LPS stimulation compared to control mice indicating a blunted response and incomplete inhibition of the pathway (37% decrease). In addition, normalized forelimb grip strength was significantly increased in IL-1Ra-treated mice. There were no changes in EDL muscle-specific force measurements, histological parameters, or motor coordination assessments in the dystrophic mice after IL-1Ra treatment. There was a significant 27% decrease in the movement time and total distance traveled by the IL-1Ra treated mice, correlating with previous studies examining effects of IL-1 on behavior. Our studies indicate partial blocking of IL-1 β with IL-1Ra significantly altered only a few behavioral and strength related disease parameters; however, treatment with inhibitors that completely block IL-1 β , pathways upstream of IL-1 β production or combining various inhibitors may produce more favorable outcomes.

and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Introduction

Duchenne muscular dystrophy (DMD) is an X-linked muscle disease characterized by inflammation and fibrosis in the skeletal muscles which results from constant cycles of muscle degeneration and regeneration [1–3]. DMD is a progressive muscle weakness disease which causes loss of ambulation by the teenage years and mortality by the third decade of life usually due to cardiovascular complications. Despite the severity of this disease, there are only limited treatment options for DMD patients with the current standard-of-care regimen being glucocorticoids (GCs) [4–6]. These drugs have been demonstrated to delay the onset of symptoms associated with DMD; however, GCs have many side effects in patients, highlighting the need for safer and more effective alternative therapies. The *mdx* mouse model, identified via a spontaneous mutation in the dystrophin gene, exhibits some of the hallmark pathologies of DMD [3,7,8]. In this model, inflammation develops in both the limbs and diaphragm at 3 weeks of age, with a peak at about age 8–10 weeks, before diminishing in the limbs but not the diaphragm [9]. Pre-clinical testing has demonstrated that anti-inflammatory drugs improve the *mdx* muscle phenotype and therefore have the potential to alleviate inflammatory pathways in DMD patients [10–13].

Inflammatory cytokines play a major role in the DMD phenotype and these include factors like tumor necrosis factor alpha (TNF α) and interleukin 1 beta (IL-1 β). Expression of TNF α in *mdx* mice has been well characterized and shown to be increased with age in the diaphragm muscle where inflammation is usually high in this model [14]. Many studies have been performed to block this signaling at various levels to improve the dystrophic phenotype by reducing necrosis, degeneration and contraction-induced injury [14–22]. Because TNF α had already been examined extensively, another cytokine of particular interest to target in DMD is IL-1 β . It has previously been shown that IL-1 β plays a role in the initiation and perpetuation of muscle pathology in both DMD and limb girdle muscular dystrophy 2B (LGMD2B) patients [23]. In addition, IL-1 β mRNA levels are higher in *mdx* mice than in controls, and reducing both the expression and activity of IL-1 β could potentially treat muscle inflammation [23]. IL-1 β is secreted as a precursor protein and becomes biologically active after undergoing proteolytic cleavage by caspase-1 [24]. IL-1 β mediates signaling via the interleukin 1 receptor (IL-1R) and downstream activation of the nuclear factor kappa B (NF κ B) pathway. Interestingly, NF κ B activity has been previously shown to be elevated in the muscle of *mdx* mice [23]. Conversely, blocking NF κ B activity has been shown to reduce the inflammatory response and IL-1 β levels in both DMD patients and *mdx* mice [11,12,25,26]. These effects are similar to those seen in patients on GCs and can potentially be used in a combinatorial manner to reduce muscle inflammation even further [5,6,27–31].

The interleukin 1 receptor antagonist (IL-1Ra) is a naturally occurring cytokine that inhibits the binding of IL-1 β to IL-1R. IL-1Ra lacks the binding domain necessary for recruiting the IL-1R accessory protein to the receptor complex; therefore, preventing downstream pro-inflammatory signaling. A synthetic form of IL-1Ra, anakinra (Kineret[®]), is a recombinant and non-glycosylated form of human IL-1Ra that has been granted approval for use in arthritis by the Food and Drug Administration (FDA). Anakinra exerts its physiological effects in a similar manner to the naturally occurring antagonist, by competitively binding to the IL-1R and neutralizing the effects of IL-1 β . The protective role of anakinra in many diseases, including those affected by inflammation, makes this compound attractive for the treatment of inflammatory diseases of the muscle, such as myositis and DMD. Since inflammation plays a detrimental role in DMD, the high level of IL-1 β in the muscles of DMD patients and *mdx* mice make this pathway an attractive target for reducing the muscle pathology in these affected individuals. We

hypothesized that the inflammatory effects of DMD would be reduced by treatment with anakinra and that, *in vivo*, *mdx* mice would have improved muscle function.

Materials and Methods

Animal care

All animal work was conducted in accordance with guidelines for the care and use of laboratory animals provided by the National Institutes of Health and protocols were approved by the Children's National Institutional Animal Care and Use Committee (IACUC) (Protocol #304-13-04). For surgery, all animals were anesthetized using ketamine/xylazine and euthanasia was performed while under anesthesia using cervical dislocation. Four-week-old female C57BL/10ScSn-Dmd^{mdx}/J (*mdx*) mice weighing 10–18 g were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were housed in individually ventilated cage system with a 12-h light-dark cycle and received standard mouse chow and water *ad libitum*. Mice were rested at least 7 days before treatment and treatment began when the mice were 5 weeks old. All functional measures were acquired in a blinded manner.

Study design

IL-1Ra (anakinra, trade name Kineret[®]) was a gift from Amgen Inc. (Thousand Oaks, CA). Our study involved daily subcutaneous injections of two groups of animals: (a) a control *mdx* group, dosed with 0.9% NaCl (n = 6), and (b) a drug-treated *mdx* group, which received IL-1Ra at 25 mg/kg/day in a 50- μ L volume of 0.9% NaCl (n = 10). Mice were randomized on the basis of body mass and were treated for 45 days, beginning at 5 weeks of age ending when they were 12 weeks old. IL-1Ra and the vehicle were injected subcutaneously, 7 days a week.

Enzyme-linked immunosorbent assay (ELISA)

Primary splenocytes were isolated at necropsy from *mdx* mice that had been treated with IL-1Ra or saline; the cells were then maintained for 24 h *in vitro*. The medium was changed, and the splenocytes were treated for 24 h with lipopolysaccharide (LPS) or LPS-free medium. IL-1 was measured in the medium from the splenocytes. IL-1 was quantified using a Quantikine IL-1 ELISA kit (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions. N = 4 for each group analyzed.

Rotarod test

Rotarod tests were performed as described previously [32,33]. In brief, mice were trained for 2 days prior to being tested twice a day for 3 consecutive days according to the following parameters: 10 rpm for 60s (the stabilization period), followed by acceleration from 10 rpm to 40 rpm (reached within the first 25s), totaling 240 s. Latency to fall (in seconds, s) was recorded, and six scores were averaged for each mouse. N = 6 saline, n = 10 IL-1Ra treated.

Grip strength testing

Grip strength was assessed using a grip strength meter as previously described [26,33]. Five successful hindlimb and forelimb strength measurements within 2 min were recorded. The maximum values for each day over a 5-day period were used for subsequent analysis, and the data were normalized to body mass and expressed as kilogram force (KGF). N = 6 saline, n = 10 IL-1Ra treated.

In vitro force measurements

Maximal force (mN) and twitch force (mN) generated by the extensor digitorum longus (EDL) muscle from the right hind limb was measured using a force transducer (Aurora Scientific, Aurora, Ontario, Canada) as previously described [11]. Specific force was calculated by dividing the maximal force generated by the EDL muscle by the cross-sectional area of the muscle (kN/m^2). $N = 4$ saline, $n = 6$ IL-1Ra treated.

Histological evaluations

Mice were anesthetized using ketamine followed by cervical dislocation in order to prevent animal suffering. Muscles were harvested and a portion of each dissected muscle (e.g., gastrocnemius, diaphragm, EDL, or heart) was placed in formalin for paraffin embedding. These tissues were later sectioned and stained with hematoxylin and eosin (H&E). The remaining portion of each tissue was embedded in Tissue-Tek optimal cutting temperature (O.C.T.) compound, (Sakura Finetek USA, Torrance, CA) and frozen in liquid nitrogen chilled isopentane for cryo-sectioning. Tissues were imaged under a light microscope with a 20X objective, and a digital image was obtained using computer software (Olympus C.A.S.T. Stereology System, Olympus America Inc., Center Valley, PA). The digital images were loaded into Image J (NIH) with additional plug-ins to count the cells. The total number of cells, centralized nuclei, peripheral nuclei, and cells with centralized nuclei were counted and analyzed for comparison between treatment groups. Fibers showing degeneration (as defined by a loss of striations and a homogeneous appearance of the fiber contents), regeneration (as defined by a basophilic cytoplasm and large peripheral or central nuclei with prominent nucleoli), and inflammatory foci per field were assessed in a blinded fashion as described previously [33].

Behavioral activity measurement

Open-field activity was measured using an open-field Digiscan apparatus (Omnitech Electronics, Columbus, OH) as described previously [33]. In brief, all mice were acclimated for 60 min daily in the week prior to data collection. Data were collected every 10 min over a 1-h period each day for 4 consecutive days. Results were calculated as mean \pm standard error of the mean (SEM) of all recordings. $N = 6$ saline, $n = 10$ IL-1Ra treated.

Statistical analysis

Statistical analyses comparing two groups at a time were performed using parametric, unpaired, two-tailed, t-tests (Graph Pad, Prism software). P-values ≤ 0.05 were considered statistically significant. Values in the graphs in the figures represent Values in the graphs represent mean \pm standard error of the mean (SEM).

Results

IL-1Ra blunted the effect of LPS on IL-1 secretion in splenocytes from *mdx* mice

To test whether IL-1Ra is effective *in vivo* in inhibiting IL-1 secretion, splenocytes from *mdx* mice treated with IL-1Ra or saline (control) were stimulated with lipopolysaccharide (LPS). The IL-1 secretion was comparable in the unstimulated splenocytes from the saline-treated mice and the IL-1Ra-treated mice, indicating that IL-1Ra treatment alone did not alter the basal level of IL-1 secretion in the *mdx* mice (Fig 1). As expected, LPS stimulation significantly increased IL-1 secretion in saline-treated *mdx* mice. There was also a significant increase in IL-




Fig 1. IL-1Ra blunted the effect of LPS on IL-1 secretion in splenocytes from *mdx* mice. Enzyme-linked immunosorbent assay (ELISA) was performed on medium from primary splenocytes isolated from *mdx* mice that had been treated with IL-1Ra or saline. Splenocytes from IL-1Ra- and saline-treated mice were isolated and stimulated with lipopolysaccharide (LPS). Medium was collected after 24 h to quantify the levels of IL-1 secreted into the medium by the splenocytes. LPS treatment significantly increased the IL-1 production in the splenocytes from control mice (groups 1–2) and from the IL-1Ra-treated mice (groups 3–4). Although not significant, this increase was blunted in the IL-1Ra and was 36% lower than the amount of secreted IL-1 in group 2. Values in the graphs represent mean \pm SEM. Statistically significant differences were determined by using parametric, unpaired, two-tailed, t-tests with a $p \leq 0.05$ being significant ($n = 4$ for each group tested).

doi:10.1371/journal.pone.0155944.g001

IL-1Ra-treated splenocytes challenged with LPS. Although it was not statistically significant, it is important to note there was 37% decrease in IL-1 secretion from LPS-stimulated splenocytes of IL-1Ra-treated *mdx* mice when compared to those from saline-treated control *mdx* mice (Fig 1). Therefore, LPS-induced IL-1 secretion was blunted in the splenocytes from mice treated with IL-1Ra when compared to those receiving saline indicating IL-1Ra only partially inhibited this pathway.

IL-1Ra treatment improves limb muscle strength in *mdx* mice

Grip strength measurements, performed to measure muscle strength, demonstrated that IL-1Ra-treated *mdx* mice showed a significant 11% increase in maximum forelimb strength measurements and a 7% increase in maximum hindlimb strength where statistical significance was not attained likely due to one outlier (Fig 2A and 2B). Mice treated with IL-1Ra exhibited significantly improved normalized forelimb grip strength (Fig 2C) and improvements in normalized hindlimb strength when compared to control animals (Fig 2D). The normalized forelimb and hindlimb grip strengths increased by approximately 11% ($p < 0.05$) and 7% ($p = 0.056$), respectively, in the mice treated with IL-1Ra when compared to the saline-injected controls (Fig 2C and 2D). Latency to fall measurements are an indicator of motor coordination, learning, and balance; however, there were no significant differences in these measurements between IL-1Ra-treated and control *mdx* mice (Fig 2E).

IL-1Ra treatment does not alter *in vitro* force generation or histological parameters in *mdx* mice

To further examine muscle strength, *in vitro* force measurements were performed. The *in vitro* twitch force (mN) and absolute force (mN) of the EDL muscle did not differ between IL-1Ra-




Fig 2. Grip strength is increased in *mdx* mice treated with IL-1Ra. Maximal strength (KGF) was measured using a grip-strength meter and normalized to body mass in kg to determine the force per kg of animal mass (KGF/KG). Animals treated with IL-1Ra (n = 10) had significantly higher (A) maximal (p = 0.047, 11% increase) and (C) normalized forelimb grip-strength (p = 0.028, 11% increase) than did control saline-treated (n = 6) animals. Hindlimb strength was measured in the same way as forelimb, and there was an increase in (B) maximal hindlimb grip strength (p = 0.100, 7% increase) and (D) normalized hindlimb strength when the means of the IL-1Ra treated (10.56 KGF/KG) and saline-injected mice (9.87 KGF/KG) were compared; this difference almost reached statistical significance (p = 0.058). There were also no significant differences in hindlimb grip strength without normalization, although a similar trend remained. (E) There were no significant differences in the latency to fall in control- (95.44s) and IL-1Ra- (99.15s) treated *mdx* mice, although the mean values showed a longer latency to fall for the IL-1Ra-treated mice. Values in the graphs represent mean ± SEM. Statistically significant differences were determined by parametric, unpaired, two-tailed, t-tests with a p ≤ 0.05 being significant.

doi:10.1371/journal.pone.0155944.g002

treated and saline-treated *mdx* mice (Fig 3A–3C). The specific force (kN/m²) and EDL mass (mg) was not significantly changed but there was a 12% reduction in specific force comparing the mean values of the IL-1Ra-treated animals which could partially be explained by the slight (not statistically significant) differences in mass of the EDL from the IL-1Ra-treated mice versus saline (9.67 mg versus 9.36 mg, Table 1). There were no significant differences in the absolute body mass, skeletal muscle (gastrocnemius, soleus) mass, or heart mass between the saline-treated and IL-1Ra-treated mice (Table 1). From histology, no differences were observed in the number of degenerating or regenerating fibers, inflammatory cells, or centralized or peripheral nuclei in the gastrocnemius muscles from the IL-1Ra-treated and control *mdx* mice (Fig 4A and 4B).

IL-1Ra treatment decreases activity in *mdx* mice

Behavioral measurements of horizontal and vertical activity were performed using an open-field Digiscan apparatus as previously described [33]. IL-1Ra treatment did not have a significant effect on either horizontal or vertical activity in IL-1Ra-treated *mdx* mice when compared




Fig 3. IL-1Ra treatment does not alter EDL muscle force. Muscle force in the extensor digitorum longus (EDL) muscle did not differ in saline-treated and IL-1Ra-treated *mdx* mice. There was a decrease in the strength capacity of the mice treated with IL-1Ra when compared to the controls for all measurements recorded: (A) twitch force, mN (5% decrease), (B) muscle force, mN (4% decrease) and (C) specific force, kN/m² (12% decrease); however, none of these differences was statistically significant. Values in the graphs represent mean ± SEM. Statistical significance was determined by parametric, unpaired, two-tailed, t-tests (n = 4 saline and n = 6 IL-1Ra).

doi:10.1371/journal.pone.0155944.g003

Table 1. Body and muscle mass in *mdx* mice after treatment with saline or IL-1Ra.

Parameters	Saline-treated	IL-1Ra-treated	p-value
Body mass, g	20.93 (0.42)	21.85 (0.31)	0.12
Gastrocnemius, mg	109.28 (5.06)	114.67 (3.00)	0.36
Soleus, mg	7.53 (0.42)	7.81 (0.29)	0.60
EDL, mg	9.36 (0.59)	9.67 (0.35)	0.66
Heart, mg	100.55 (5.73)	100.29 (2.68)	0.96

There were no statistically significant differences in the overall body mass or the masses of the gastrocnemius, soleus, extensor digitorum longus (EDL), or heart between the IL-1Ra-treated and control saline-treated mice. Muscle mass was expressed as the average of the left and right muscle, where applicable, and also as a percentage of the total body weight. Values are expressed as mean, with SEM in parentheses. No significant differences were determined as calculated by parametric, unpaired, two-tailed, t-tests; p-values are indicated.

doi:10.1371/journal.pone.0155944.t001

to saline-injected mice (Fig 5; data not shown). Movement time and total distance traveled were significantly decreased (by 27%) in the IL-1Ra-treated mice when compared to the saline-treated mice (Fig 5B and 5C).

Discussion

During inflammatory processes, IL-1 β is produced by several cell types in response to activation of a variety of innate immune receptors, including the toll-like receptor (TLR) superfamily. Stimulation of IL-1 β and subsequent binding to the IL-1R activates the pro-inflammatory NF κ B pathway. IL-1 β signaling is controlled by IL-1Ra, a natural antagonist of IL-1R, and overexpression of IL-1 β has been implicated in the pathology of a wide variety of human




Fig 4. IL-1Ra treatment does not alleviate muscle pathology in *mdx* mice. Degenerating (A) and regenerating (B) muscle fibers were quantified in gastrocnemius muscle. Inflammatory cells were also quantified in sections from saline- and IL-1Ra-treated mice (C). Nuclei from sections were scored and quantified as either centralized (D) or peripheral (E). The number of fibers with centralized nuclei (F) was quantified by treatment group. Values in the graphs represent mean \pm SEM. Statistical significance was determined by parametric, unpaired, two-tailed, t-tests (N = 5, saline; N = 9, IL-1Ra).

doi:10.1371/journal.pone.0155944.g004




Fig 5. IL-1Ra treatment decreases activity and increases rest time in *mdx* mice. Horizontal activity (A) was measured using an open-field Digiscan apparatus and did not differ significantly between IL-1Ra- and saline-treated mice. During the Digiscan measurements, the (B) movement time (26% decrease in the IL-1Ra-treated mice vs. control, $p = 0.0075$) and (C) total distance traveled (27% decrease in the IL-1Ra-treated mice vs. control, $p = 0.008$) were recorded and were significantly lower in the IL-1Ra-treated mice than in the controls. Graphs represent mean \pm SEM and statistically significant differences were determined by parametric, unpaired, two-tailed, t-tests with a $p \leq 0.05$ being significant. ($n = 6$ saline, $n = 10$ IL-1Ra).

doi:10.1371/journal.pone.0155944.g005

diseases associated with chronic inflammation. Development of inhibitors such as anakinra have been shown to be effective in many diseases with an inflammatory component including: inhibiting apoptotic events during experimental acute myocardial infarction [34], improving symptoms of type 2 diabetes [35–38] and reducing the symptoms of rheumatoid arthritis (RA) in clinical trials [39,40]. Improvements in auto-inflammatory diseases, including Muckle-Wells syndrome (MWS) [41] and gout [42] have also been described after using anakinra. Since inflammation is a major player in DMD, the IL-1 β pathway is expected to play a role in the initiation and perpetuation of the muscle pathology in DMD. Muscle inflammation and necrosis is also evident in the *mdx* mouse model; therefore, IL-1Ra treatment in pre-clinical studies could prevent the inflammatory effects of systemic IL-1 β secretion on IL-1R activation potentially limiting cellular inflammation. In addition, it is known that in the *mdx* mouse model of DMD, there is an increase in the expression of TNF- α and IL-1 β prior to disease onset [23]. IL-1Ra is already FDA-approved making this drug a good candidate to try to inhibit IL-1 β upregulation and prevent the associated downstream signaling.

To date, many preclinical studies have focused on pharmacological treatments to inhibit TNF- α as a potential treatment for DMD. Several of the drugs tested have been shown to ameliorate the muscle pathologies associated with the *mdx* phenotype [14–22]. In the present study, inhibiting IL-1 β in the *mdx* model was tested using a synthetic inhibitor of IL-1R, IL-1Ra, treating *mdx* mice for 45 days. The dosing regimen selected here, 25mg/kg daily, was based on a previous study that demonstrated efficacy in a model of alcoholic steatohepatitis in mice [43]. To assess whether IL-1Ra had engaged the target, we performed an *in vitro* stimulation assay using LPS to activate splenocytes collected from treated and untreated animals. Here, we saw a blunted effect of IL-1Ra on splenocytes treated with LPS (27% less than control LPS-stimulated splenocytes), indicating IL-1Ra incompletely inhibited IL-1 under our conditions, thus allowing signaling to persist even after treatment (Fig 1).

In addition to examining signaling effects of IL-1Ra, strength testing was also performed and revealed significantly improved forelimb gripstrength and a trend for hindlimb gripstrength, though not significant, toward increasing (Fig 2). No changes were detected in latency to fall (Fig 2E), or muscle force (twitch, maximal, or specific force, Fig 3). Open-field activity measures were mainly down-regulated in the mice treated with IL-1Ra (Fig 5). One possible explanation for the 27% decrease in movement in the IL-1Ra-treated mice could be that the mice are nauseous and therefore less likely to move about the cage. This is certainly reasonable to consider since this is one of the potential side effects of IL-1Ra in humans (Fig 5). Increased

grip strength and decreased open-field activity measures could have been caused by differential effects of IL-1 signaling. For example, it is known that immobilization stress induces IL-1 β in rats [44,45], IL-1 administration induces stress [46], exposure to acute stress induces IL-1 expression in rodents [47]. IL-1R-null mice show decreased anxiety, and conversely IL-1Ra-null mice show increased anxiety as they age [48,49]. Additionally, mice with IL-1 β overexpression specifically in the hippocampus (IL-1 β^{XAT}) demonstrate increased locomotion, the converse of what was seen in these studies inhibiting that pathway [50]. IL-1 could be released to mediate a stress response, and when the natural inhibitor of IL-1, IL-1Ra, is genetically removed, the animals elicit an increased stress response [49]. For this study, the mice were handled prior to the grip strength measurement, and although they had become acclimated during the week before the measurements were collected, grip strength could have been improved because of increases in IL-1 β leading to behavioral stress response. True muscle force is measured by the *in vitro* force measurements, because these measurements are not confounded by volition. *In vitro* force was not changed in our study after IL-1Ra treatment, indicating that IL-1Ra did not improve muscle strength possibly due to an incomplete inhibition of this pathway.

The skeletal muscles from the mice treated with IL-1Ra had no differences in histological measurements including inflammatory foci, muscle fibers with centralized nuclei, regenerating fibers, or degenerating fibers when compared to controls. This can also be explained by IL-1Ra being a weak inhibitor of the pathway (Fig 4). There are several other factors that could provide an explanation for this including: lack of potency, dosage, duration of treatment, and the role of the IL-1 pathway in muscle disease progression at the time of treatment. A longer-term study could reveal improved cellular patterning in IL-1Ra-treated *mdx* mice and indicate that IL-1Ra can indeed diminish the secretion of IL-1; however, this possibility still needs to be tested. For this study, treatment was administered after the onset of skeletal muscle necrosis in *mdx* mice and others have shown that inhibiting another inflammatory cytokine, TNF α , using Remicade[®] (an anti-TNF α antibody) at seven days of age delayed onset of acute necrosis at 21 days in *mdx* mice [22]. Treating mice at earlier time points with IL-1Ra could be considered for future experiments to examine the full potential of this drug at all stages of the disease phenotype in the *mdx* mice. Interestingly, at 12 weeks there were no significant pathological changes found after Remicade[®] treatment as we have shown after IL-1Ra treatment [22]. To overcome this challenge with the stabilized *mdx* muscle phenotype, older *mdx* mice could be treated with IL-1Ra and challenged using a treadmill to exacerbate the disease phenotype at this stage and examine additional effects from this treatment on dystrophic muscles similarly to what was done with TNF α inhibition [20]. Lastly, it is possible that inhibition of TNF α could be more efficacious than IL-1Ra treatment in the *mdx* mice; however, considerations have to be taken for examining cardiac function as long-term TNF α inhibition has been demonstrated to have a negative impact on heart function [51].

Overall, the dose of IL-1Ra used here may have been enough to elicit a behavioral response but insufficient to completely block the inflammatory signaling cascade and associated phenotype in the skeletal muscles of the *mdx* mice. In order to further examine the inhibition of IL-1 and the benefits of down-regulating the secretion of this inflammatory factor, other IL-1R inhibitors could also be examined in preclinical trials. They could be compared with IL-1Ra to determine whether or not they are more potent inhibitors and, if so, what histological and functional outcomes might improve from their use. Others have examined the possibility of decreasing inflammation by using exon-skipping technology targeting IL-1RACp [52]. Targeting IL-1R can have broad applications for many inflammatory diseases, and the mechanisms of its inhibition are important to understand in order to decrease inflammation associated with the disease. The goal of the ongoing studies in our laboratory is to broaden the therapeutic options for DMD patients and their families beyond prolonged steroid regimens. In this short-

term study of *mdx* mice, which have a milder phenotype than DMD patients, IL-1Ra treatment displayed an improvement in some functional parameters for muscle strength when compared to saline-treated mice; however, these changes could have been a result of the behavioral effects of the treatment. Optimization of the dosage and timing of the IL-1Ra treatment is clearly needed to clarify whether a greater inhibition of the IL-1 β signaling pathway (and resulting clinical improvement) can be achieved in DMD.

Acknowledgments

We would like to thank Heather M. Alger for input when writing the manuscript.

Author Contributions

Conceived and designed the experiments: AS SR JV KN. Performed the experiments: AS SR JV. Analyzed the data: AS SR JV MBK KN. Wrote the paper: AS SR MBK KN.

References

1. Hoffman EP, Brown RH Jr., Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. *Cell* 51: 919–928. PMID: [3319190](#)
2. Hoffman EP, Knudson CM, Campbell KP, Kunkel LM (1987) Subcellular fractionation of dystrophin to the triads of skeletal muscle. *Nature* 330: 754–758. PMID: [2447503](#)
3. Hoffman EP, Monaco AP, Feener CC, Kunkel LM (1987) Conservation of the Duchenne muscular dystrophy gene in mice and humans. *Science* 238: 347–350. PMID: [3659917](#)
4. Manzur AY, Kinali M, Muntoni F (2008) Update on the management of Duchenne muscular dystrophy. *Arch Dis Child* 93: 986–990. doi: [10.1136/adc.2007.118141](#) PMID: [18667451](#)
5. Manzur AY, Kuntzer T, Pike M, Swan A (2008) Glucocorticoid corticosteroids for Duchenne muscular dystrophy. *Cochrane Database Syst Rev*: CD003725. doi: [10.1002/14651858.CD003725.pub3](#) PMID: [18254031](#)
6. Markham LW, Kinnett K, Wong BL, Woodrow Benson D, Cripe LH (2008) Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. *Neuromuscular disorders: NMD* 18: 365–370. doi: [10.1016/j.nmd.2008.03.002](#) PMID: [18436445](#)
7. Bulfield G, Siller WG, Wight PA, Moore KJ (1984) X chromosome-linked muscular dystrophy (*mdx*) in the mouse. *Proceedings of the National Academy of Sciences of the United States of America* 81: 1189–1192. PMID: [6583703](#)
8. Grounds MD, Radley HG, Lynch GS, Nagaraju K, De Luca A (2008) Towards developing standard operating procedures for pre-clinical testing in the *mdx* mouse model of Duchenne muscular dystrophy. *Neurobiol Dis* 31: 1–19. doi: [10.1016/j.nbd.2008.03.008](#) PMID: [18499465](#)
9. Tanabe Y, Esaki K, Nomura T (1986) Skeletal muscle pathology in X chromosome-linked muscular dystrophy (*mdx*) mouse. *Acta neuropathologica* 69: 91–95. PMID: [3962599](#)
10. Huang P, Zhao XS, Fields M, Ransohoff RM, Zhou L (2009) Imatinib attenuates skeletal muscle dystrophy in *mdx* mice. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology* 23: 2539–2548.
11. Heier CR, Damsker JM, Yu Q, Dillingham BC, Huynh T, Van der Meulen JH, et al. (2013) VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. *EMBO Mol Med* 5: 1569–1585. doi: [10.1002/emmm.201302621](#) PMID: [24014378](#)
12. Messina S, Bitto A, Aguenouz M, Minutoli L, Monici MC, Altavilla D, et al. (2006) Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in *Mdx* mice. *Experimental neurology* 198: 234–241. PMID: [16410003](#)
13. Tang Y, Reay DP, Salay MN, Mi MY, Clemens PR, Guttridge DC, et al. (2010) Inhibition of the IKK/NF-kappaB pathway by AAV gene transfer improves muscle regeneration in older *mdx* mice. *Gene Ther* 17: 1476–1483. doi: [10.1038/gt.2010.110](#) PMID: [20720575](#)
14. Barros Maranhao J, de Oliveira Moreira D, Mauricio AF, de Carvalho SC, Ferretti R, Pereira JA, et al. (2015) Changes in caldesmon, TNF-alpha, TGF-beta and MyoD levels during the progression of skeletal muscle dystrophy in *mdx* mice: a comparative analysis of the quadriceps, diaphragm and intrinsic laryngeal muscles. *Int J Exp Pathol* 96: 285–293. doi: [10.1111/iep.12142](#) PMID: [26515458](#)
15. Pierno S, Nico B, Burdi R, Liantonio A, Didonna MP, Cippone V, et al. (2007) Role of tumour necrosis factor alpha, but not of cyclo-oxygenase-2-derived eicosanoids, on functional and morphological

- indices of dystrophic progression in *mdx* mice: a pharmacological approach. *Neuropathol Appl Neurobiol* 33: 344–359. PMID: [17493014](#)
16. de Senzi Moraes Pinto R, Ferretti R, Moraes LH, Neto HS, Marques MJ, Minatel E (2013) N-acetylcysteine treatment reduces TNF-alpha levels and myonecrosis in diaphragm muscle of *mdx* mice. *Clin Nutr* 32: 472–475. doi: [10.1016/j.clnu.2012.06.001](#) PMID: [22727548](#)
 17. Machado RV, Mauricio AF, Taniguti AP, Ferretti R, Neto HS, Marques MJ (2011) Eicosapentaenoic acid decreases TNF-alpha and protects dystrophic muscles of *mdx* mice from degeneration. *J Neuroimmunol* 232: 145–150. doi: [10.1016/j.jneuroim.2010.10.032](#) PMID: [21131061](#)
 18. Piers AT, Lavin T, Radley-Crabb HG, Bakker AJ, Grounds MD, Pinniger GJ (2011) Blockade of TNF in vivo using cV1q antibody reduces contractile dysfunction of skeletal muscle in response to eccentric exercise in dystrophic *mdx* and normal mice. *Neuromuscul Disord* 21: 132–141. doi: [10.1016/j.nmd.2010.09.013](#) PMID: [21055937](#)
 19. Waters FJ, Shavlakadze T, McIlldowie MJ, Piggott MJ, Grounds MD (2010) Use of pifithrin to inhibit p53-mediated signalling of TNF in dystrophic muscles of *mdx* mice. *Mol Cell Biochem* 337: 119–131. doi: [10.1007/s11010-009-0291-2](#) PMID: [19859789](#)
 20. Radley HG, Davies MJ, Grounds MD (2008) Reduced muscle necrosis and long-term benefits in dystrophic *mdx* mice after cV1q (blockade of TNF) treatment. *Neuromuscul Disord* 18: 227–238. doi: [10.1016/j.nmd.2007.11.002](#) PMID: [18207402](#)
 21. Grounds MD, Davies M, Torrisi J, Shavlakadze T, White J, Hodgetts S (2005) Silencing TNFalpha activity by using Remicade or Enbrel blocks inflammation in whole muscle grafts: an in vivo bioassay to assess the efficacy of anti-cytokine drugs in mice. *Cell Tissue Res* 320: 509–515. PMID: [15846506](#)
 22. Grounds MD, Torrisi J (2004) Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis. *FASEB J* 18: 676–682. PMID: [15054089](#)
 23. Rawat R, Cohen TV, Ampong B, Francia D, Henriques-Pons A, Hoffman EP, et al. (2010) Inflammatory up-regulation and activation in dysferlin-deficient skeletal muscle. *The American journal of pathology* 176: 2891–2900. doi: [10.2353/ajpath.2010.090058](#) PMID: [20413686](#)
 24. Dinarello CA (1996) Biologic basis for interleukin-1 in disease. *Blood* 87: 2095–2147. PMID: [8630372](#)
 25. Messina S, Altavilla D, Aguenouz M, Seminara P, Minutoli L, Monici MC, et al. (2006) Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and enhances muscle function in *mdx* mice. *The American journal of pathology* 168: 918–926. PMID: [16507907](#)
 26. Huynh T, Uaesoontrachoon K, Quinn JL, Tatem KS, Heier CR, Van Der Meulen JH, et al. (2013) Selective modulation through the glucocorticoid receptor ameliorates muscle pathology in *mdx* mice. *J Pathol* 231: 223–235. doi: [10.1002/path.4231](#) PMID: [23794417](#)
 27. Angelini C, Pegoraro E, Turella E, Intino MT, Pini A, Costa C (1994) Deflazacort in Duchenne dystrophy: study of long-term effect. *Muscle & nerve* 17: 386–391.
 28. Biggar WD, Harris VA, Eliasoph L, Alman B (2006) Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. *Neuromuscular disorders: NMD* 16: 249–255. PMID: [16545568](#)
 29. Griggs RC, Moxley RT 3rd, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, et al. (1991) Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. *Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol* 48: 383–388. PMID: [2012511](#)
 30. Griggs RC, Moxley RT 3rd, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, et al. (1993) Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). *Neurology* 43: 520–527. PMID: [8450994](#)
 31. Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, et al. (1989) Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. *The New England journal of medicine* 320: 1592–1597. PMID: [2657428](#)
 32. Aro AA, Freitas KM, Foglio MA, Carvalho JE, Dolder H, Gomes L, et al. (2013) Effect of the *Arrabidaea chica* extract on collagen fiber organization during healing of partially transected tendon. *Life sciences* 92: 799–807. doi: [10.1016/j.lfs.2013.02.011](#) PMID: [23454166](#)
 33. Spurney CF, Gordish-Dressman H, Guerron AD, Sali A, Pandey GS, Rawat R, et al. (2009) Preclinical drug trials in the *mdx* mouse: assessment of reliable and sensitive outcome measures. *Muscle & nerve* 39: 591–602.
 34. Abbate A, Salloum FN, Vecile E, Das A, Hoke NN, Straino S, et al. (2008) Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. *Circulation* 117: 2670–2683. doi: [10.1161/CIRCULATIONAHA.107.740233](#) PMID: [18474815](#)

35. Mandrup-Poulsen T, Zumsteg U, Reimers J, Pociot F, Morch L, Helqvist S, et al. (1993) Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic beta-cell destruction in insulin-dependent diabetes mellitus. *Cytokine* 5: 185–191. PMID: [8218929](#)
36. Koivisto VA, Leirisalo-Repo M, Ebeling P, Tuominen JA, Knip M, Turunen U, et al. (1993) Seven years of remission in a type I diabetic patient. *Diabetes care* 16: 990–995. PMID: [8359107](#)
37. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T (2009) Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. *Diabetes care* 32: 1663–1668. doi: [10.2337/dc09-0533](#) PMID: [19542207](#)
38. Lacraz G, Giroix MH, Kassis N, Coulaud J, Galinier A, Noll C, et al. (2009) Islet endothelial activation and oxidative stress gene expression is reduced by IL-1Ra treatment in the type 2 diabetic GK rat. *PloS one* 4: e6963. doi: [10.1371/journal.pone.0006963](#) PMID: [19742300](#)
39. Mertens M, Singh JA (2009) Anakinra for rheumatoid arthritis: a systematic review. *J Rheumatol* 36: 1118–1125. doi: [10.3899/jrheum.090074](#) PMID: [19447938](#)
40. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. *Arthritis and rheumatism* 41: 2196–2204. PMID: [9870876](#)
41. Dalgic B, Egritas O, Sari S, Cuisset L (2007) A variant Muckle-Wells syndrome with a novel mutation in CIAS1 gene responding to anakinra. *Pediatric nephrology* 22: 1391–1394. PMID: [17486372](#)
42. So A, De Smedt T, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. *Arthritis research & therapy* 9: R28.
43. Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V, et al. (2012) IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. *J Clin Invest* 122: 3476–3489. doi: [10.1172/JCI60777](#) PMID: [22945633](#)
44. Tringali G, Dello Russo C, Preziosi P, Navarra P (2000) Interleukin-1 in the central nervous system: from physiology to pathology. *Therapie* 55: 171–175. PMID: [10860021](#)
45. Minami M, Kuraishi Y, Yamaguchi T, Nakai S, Hirai Y, Satoh M (1991) Immobilization stress induces interleukin-1 beta mRNA in the rat hypothalamus. *Neurosci Lett* 123: 254–256. PMID: [2027540](#)
46. Cragnolini AB, Schiöth HB, Scimone TN (2006) Anxiety-like behavior induced by IL-1beta is modulated by alpha-MSH through central melanocortin-4 receptors. *Peptides* 27: 1451–1456. PMID: [16325304](#)
47. Nguyen KT, Deak T, Owens SM, Kohno T, Fleshner M, Watkins LR, et al. (1998) Exposure to acute stress induces brain interleukin-1beta protein in the rat. *J Neurosci* 18: 2239–2246. PMID: [9482808](#)
48. Koo JW, Duman RS (2009) Interleukin-1 receptor null mutant mice show decreased anxiety-like behavior and enhanced fear memory. *Neurosci Lett* 456: 39–43. doi: [10.1016/j.neulet.2009.03.068](#) PMID: [19429130](#)
49. Wakabayashi C, Numakawa T, Odaka H, Ooshima Y, Kiyama Y, Manabe T, et al. (2015) IL-1 receptor antagonist (IL-1Ra) knockout mice show anxiety-like behavior by aging. *Neurosci Lett* 599: 20–25. doi: [10.1016/j.neulet.2015.05.019](#) PMID: [26002078](#)
50. Hein AM, Zarcone TJ, Parfitt DB, Matousek SB, Carbonari DM, Olschowka JA, et al. (2012) Behavioral, structural and molecular changes following long-term hippocampal IL-1beta overexpression in transgenic mice. *J Neuroimmune Pharmacol* 7: 145–155. doi: [10.1007/s11481-011-9294-3](#) PMID: [21748283](#)
51. Ermolova NV, Martinez L, Vetrone SA, Jordan MC, Roos KP, Sweeney HL, et al. (2014) Long-term administration of the TNF blocking drug Remicade (cV1q) to *mdx* mice reduces skeletal and cardiac muscle fibrosis, but negatively impacts cardiac function. *Neuromuscul Disord* 24: 583–595. doi: [10.1016/j.nmd.2014.04.006](#) PMID: [24844454](#)
52. Yilmaz-Elis AS, Aartsma-Rus A, t Hoen PA, Safdar H, Breukel C, van Vlijmen BJ, et al. (2013) Inhibition of IL-1 Signaling by Antisense Oligonucleotide-mediated Exon Skipping of IL-1 Receptor Accessory Protein (IL-1RAcP). *Mol Ther Nucleic Acids* 2: e66. doi: [10.1038/mtna.2012.58](#) PMID: [23340324](#)